This study aims to test the safety and effectiveness of RGN-259 eye drops compared to a placebo (a treatment with no active drug) for treating Neurotrophic Keratopathy (NK). NK is a disease that affects the cornea, the clear front part of the eye, due to damage to the eye's nerve supply. This damage leads to a lack of feeling in the eye, causing problems like reduced tear production and poor healing of the cornea.

To join the study, you must be 18 or older, provide consent, and meet specific eye health criteria. You should not have any conditions or recent surgeries that could interfere with the study. Women should use birth control, and both men and women must agree to avoid pregnancy during the study.

Key Points to Consider:

• The study requires multiple visits to the study center.
• Participants will be given either the RGN-259 eye drops or a placebo.
• Some risks may include irritation or discomfort from the eye drops.